CSL Behring's Japanese subsidiary announced that Edward Wright would become president of the Japanese subsidiary, effective 19 October 2026. Wright has more than 20 years of experience in the pharmaceutical, government and financial sectors and extensive knowledge of Japan's healthcare system and regulatory environment.
CSL Behring K.K. announced that Edward Wright would become president of its Japanese subsidiary, effective 19 October 2026. The announcement was made through the company's press release, and the appointment is expected to be implemented as a formal personnel change.
Wright has more than 20 years of experience in the pharmaceutical industry, government agencies and the financial industry, and has held leadership roles across a broad range of areas, including commercial operations, business development, market access and government affairs. Through his extensive experience in Japan, he has developed deep knowledge of Japan's healthcare system and its policy and regulatory environment.
Wright previously served as general manager and president of Clinigen K.K., where he was also responsible for the South Korean business. Before that, he held senior positions at Bayer and Novartis in specialty care, business development and alliance management. Earlier in his career, he served as a life sciences officer at the British Embassy in Japan.
Wright holds a BA in chemistry from the University of Oxford and a PhD in chemistry from the University of Cambridge. He also holds an MBA from INSEAD and a BSc in international relations from the London School of Economics (LSE).